The firm brings unique experience to tracking, assessing and explaining regulatory and reimbursement policy that affect the biopharmaceutical industry. The company’s goal is to advance mutual understanding among policymakers, business executives and the investment community, in the belief that a deeper understanding of policy leads to better business, and a deeper understanding of business leads to better policy.
Member Sign In:
- Breast Cancer “Master Protocol” Meeting: FDA, Industry Not Barriers, But Other Stakeholders Need To Learn To Collaborate Oct. 22, 2014
- Delaying, Denying, Refusing Inspection Revised Guidance Adds Examples of Reasonable Explanations Oct. 22, 2014
- Vertex Wins Approval Vote For Broader Kalydeco CF Use; FDA Urges “Flexibility” For Known Drug, Known Disease Oct. 22, 2014
See More Research Notes